AV 101
Alternative Names: 4-Chlorokynurenine - VistaGen; 4-CL-KYN; 7-CL-KYNA; AV-101; L-4-chlorokynurenine; L-4-CL-KYNLatest Information Update: 28 Jan 2026
At a glance
- Originator Artemis Neuroscience
- Developer Baylor College of Medicine; Jade Biosciences; National Institute of Mental Health; VistaGen Therapeutics
- Class Analgesics; Antidepressants; Antiepileptic drugs; Antihypertensives; Antiparkinsonians; Behavioural disorder therapies; Butyric acids; Neuroprotectants; Small molecules
- Mechanism of Action Kynurenine modulators; NMDA receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Hypertension
- Phase II Major depressive disorder
- No development reported Epilepsy; Huntington's disease; Neurological disorders; Neuropathic pain; Parkinson's disease; Psychiatric disorders; Suicidal ideation
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for phase-I development in Neurological-disorders(In volunteers) in USA (PO)
- 28 Jan 2026 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in USA (PO)
- 28 Apr 2025 Aerovate Therapeutics has merged with Jade Biosciences to form Jade Biosciences